Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 4/20 | 0.39 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | TGM1 | P22735 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26926622 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL18384078 | 0.90 | USP2 (0.42) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL14115788 | 0.85 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL16980139 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL6635899 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL7695181 | 0.83 | USP2 (0.43) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2450051 | 0.82 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL31306282 | 0.81 | HPGD (0.41) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL563630 | 0.81 | USP2 (0.53) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL16837814 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2018119441-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2709451-B1 | N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9206200-B2 | N-linked lactam M1 receptor positive allosteric mogulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| WO-2010089119-A1 | HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-08-12 | — | — | WO | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| CN-1249057-C | Chromenylmethylpyrimidine diamines as antibacterial agents | BASLIER PHARMACEUTICAL S A (CH) | 2006-04-05 | — | — | CN | disclosed |
| US-6818649-B2 | 5-(8-ALKOXY)-2,2-SUBSTITUTED-2H-CHROMEN-6-YLMETHYL)-PYRIMIDINE-2,4 -DIAMINE DERIVATIVES USEFUL FOR TREATING INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-11-16 | — | — | US | disclosed |
| CN-1507445-A | Chromenylmethyl pyrimidinediamines as antibacterial agents | ��������ҩ�ɷ�����˾ | 2004-06-23 | — | — | CN | disclosed |
| US-20030144246-A1 | Chromenylmethyl pyrimidinediamines as antibacterial agents | BASILEA PHARMACEUTICA AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| EP-1278742-A1 | CHROMENYLMETHYLPYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | Basilea Pharmaceutica AG (CH) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083476-A1 | CHROMENYLMETHYL PYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | USP2 70/4885SMN1; SMN2 2772/4885HPGD 4518/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | USP2 70/4885SMN1; SMN2 2772/4885HPGD 4518/4885 |
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | GPR4, FABP6, GIPR | USP2 3982/4885SMN1; SMN2 4190/4885HPGD 593/4885 |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | USP2 3961/4885SMN1; SMN2 1001/4885HPGD 667/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | USP2 2291/4885SMN1; SMN2 4785/4885HPGD 987/4885 |
| US-20030144246-A1 | Chromenylmethyl pyrimidinediamines as antibacterial agents | TK1, TPMT, CTSL | USP2 4403/4885SMN1; SMN2 4619/4885HPGD 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.